Hormone-suppressing treatments for aggressive prostate cancer may cause heart attacks to occur 2.5 years earlier in men with risk factors for heart disease.
High blood levels of alpha-tocopherol or gamma-tocopherol, (vitamin E forms), cut risk of prostate cancer 50% in new analysis of ATBC trial, supporting original conclusions. Dietary, but not supplementary, vitamin E, is key.
Dietary gamma-tocopherol was associated with a 32% reduction in the risk of advanced prostate cancer, according to a National Cancer Institute researcher (Cancer Epidemiology Biomarkers & Prevention journal).
"High intake of food items rich in phytoestrogens (flaxseed, sunflower seeds, berries, peanuts, beans and soy) was associated with a monotonically decreasing overall risk [26%] of prostate cancer."
The plant lignan secoisolariciresinol diglycoside (SDG) from flaxseed may be antitumorigenic due to its estrogenic and antiestrogenic effects, anti-oxidative effects, antiproliferative and anti-aromatase effects. Review of studies showing anticarcinogenic
Diverse nonhematopoietic biological effects of the cytokine erythropoietin shows that it promotes angiogenesis. Recombinant human erythropoietin therapy in prostate cancer will be studied...
Prostate tumors grew about 30% to 40% slower in the men taking flaxseed whether or not they followed a low-fat diet, Duke researchers told colleagues (June 1-5, Amer Soc Clinical Oncology).
"Some prostate cancers grow so slowly that they never become life-threatening, especially in elderly men who may die of other causes before the cancer causes problems," explained Wong. "But other men develop complications and die from their cancer making
"Just as a failure to treat a potentially lethal prostate cancer is generally considered inappropriate from a quality-of-care perspective, overtreatment of lower-risk cancers is also not in the patient's best interest"...
Because Prostate cancer often grows so slowly that it never become life-threatening in older men who may may die first of other causes. A long-running debate in the medica
R. Burns, B. Walsh, S. O’Neill, and C. O’Neill. Health Policy, 108 (2–3):
269-276(2012)http://dx.doi.org/10.1016/j.healthpol.2012.08.014 (Eurobarometer).